NCT06554613View on ClinicalTrials.gov

Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

May 31, 2028

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Olanzapine

Olanzapine 5mg qd (once daily), q3w(every 3 weeks), oral therapy，Administered continuously for 6-8 weeks.

DRUG

Nivolumab

Nivolumab，Infused intravenously once every 3 weeks at a dose of 2mg/kg, with a continuous 21-day treatment period constituting one treatment cycle.

All Listed Sponsors
lead

Second Affiliated Hospital of Nanchang University

OTHER

NCT06554613 - Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC | Biotech Hunter | Biotech Hunter